Aurobindo Pharma Ltd - Slight Dip in Profitability Due to Temporary Activities
Quarterly revenue reached Rs. 7,796 crore, reflecting an 8% y-o-y and 3% q-o-q increase, exceeding our estimates by 1%, while PAT was Rs. 817 crore
74 Views
Aurobindo Pharma Ltd - Fell Short of Expectations Amidst Mixed Market Performance
Aurobindo Pharma's Q2FY25 results were below expectations, with US revenue of $421 Mn showing minimal growth QoQ , injectable sales experienced a...
154 Views
Aurobindo Pharma Ltd - Fall Short of Expectations Amidst Mixed Market Performance
Gross margins decreased by 23 basis points QoQ, and EBITDA margins fell by 67 basis points QoQ, reflecting the pressure on profitability from...
145 Views
Aurobindo Pharma (4QFY24): Strong Q4, Eugia’s USFDA Issues Key Concern. Maintain ADD
EBITDA (+68% YoY) was led by 17% sales growth (-4% QoQ US but up 18% YoY, +10% EU, and +49% YoY in growth markets), higher gross margin (+490 bps YoY)
251 Views
Aurobindo Pharma (4QFY24): Strong Q4, Eugia’s USFDA Issues Key Concern.
ARBP expects to maintain US oral solid business growth momentum, led by new launches and volume gain in the base business
247 Views